UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

November 7, 2019 (November 7, 2019)

Date of Report (date of earliest event reported)

DENTSPLY SIRONA Inc.

(Exact name of registrant as specified in its charter)

0-16211

39-1434669 (I.R.S. Employer Identification No.)

Delaware (State or other jurisdiction of incorporation or organization)

13320 Ballantyne Corporate Place,

(Commission File Number)

28277-3607 (Zip Code)

(844) 848-0137

Charlotte

Registrant's telephone number, including area code

North Carolina

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

(Address of Principal Executive Offices)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$0.01 per share	XRAY	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company \Box

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

0

Item 2.02. - Results of Operations and Financial Condition

The following information is furnished pursuant to Item 2.02, "Results of Operations and Financial Condition."

On November 7, 2019, DENTSPLY SIRONA Inc. (the "Company") issued a press release disclosing its third quarter sales and earnings. This earnings release references net sales, excluding precious metal content, and net income, adjusted for certain charges, both of which are considered measures not calculated in accordance with generally accepted accounting principles in the United States of America (non-US GAAP measures). Due to the fluctuations of precious metal prices and because the precious metal content of the Company's sales is largely a pass-through to customers and has minimal effect on earnings, the Company reports sales both with and without precious metal content to show the Company's performance independent of precious metal price volatility and to enhance comparability of performance between periods. Earnings from operations, adjusted for certain charges, are presented to enhance the comparability between periods. A copy of the Company's press release is attached hereto as Exhibit 99.1 and is hereby incorporated by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No. Description

<u>99.1</u> DENTSPLY SIRONA Inc. press release, dated November 7, 2019.

104 Cover Page Interactive Data File (embedded within the Inline XBRL Document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

DENTSPLY SIRONA Inc.

By: /s/ Keith J. Ebling

Keith J. Ebling, Executive Vice President,

General Counsel and Secretary

Date: November 7, 2019



THE DENTAL SOLUTIONS COMPANYTH

Dentsply Sirona Reports Third Quarter 2019 Financial Performance

- Reported O3 revenues of \$962 million
- Revenues increased 3.7% on a Reported basis, and increased 7.5% on an Internal sales growth basis
- GAAP EPS of \$0.38 increased 192% YoY. Non-GAAP EPS of \$0.57 increased 51% YoY^[1]
- Operating Income increased 139% YoY to \$110 million; Non-GAAP Operating Income grew 43% YoY to \$172 million
- Company raises its FY19 Non-GAAP EPS Guidance

CHARLOTTE, NC., November 7, 2019 - DENTSPLY SIRONA Inc. ("Dentsply Sirona") (Nasdaq: XRAY), the Dental Solutions Company, today announced its financial results for the three months ended September 30, 2019.

Don Casey, Chief Executive Officer, commented; "We are pleased to report solid third quarter results and encouraged that the Company continues to demonstrate good progress against our stated restructuring goals of accelerating growth, improving margins and simplifying the organization. The key to our third quarter performance was the success of our new product launches, particularly the Primescan Digital Impression System, and we are encouraged by the positive reception to the many new products we launched at Dentsply Sirona World in October. Revenue growth and our comprehensive cost savings programs contributed to significant margin expansion in the third quarter of 2019. While we still have a lot of work to do, we are convinced that the ongoing execution of our restructuring plan will continue to drive strong financial performance and create significant value for our shareholders."

Operating Financial Results (GAAP)

		Third Quarter	
(in millions, except per share data and percentages)	2019	2018	% Change
Net sales	\$ 962	\$ 928	3.7 %
Operating income	\$ 110	\$ 46	139 %
Net income per common share - diluted	0.38	0.13	192 %

Operating Financial Results (non-GAAP)^[1]

		Third Quarter	
(in millions, except per share data and percentages)	2019	2018	% Change
Net sales	\$ 951	\$ 924	2.9 %
Internal sales growth ^[2]			7.5 %
Operating income	\$ 172	\$ 120	43 %
Adjusted EPS	0.57	0.38	51 %

^[1] Non-GAAP net sales, internal sales growth, operating income and adjusted EPS are results that are non-GAAP financial measures which exclude certain items. Please refer to the tables at the end of this release for a reconciliation between GAAP and non-GAAP measures. ^[2] The Company defines "internal" sales growth as constant currency sales growth excluding the impacts of net acquisitions and divestitures and discontinued products.

Cash Flow and Liquidity

Operating cash flow in the third quarter was \$159 million, up \$34 million, or up 27% as compared to the prior year period. Free cash flow, which represents operating cash flow, less capital expenditures, was \$136 million in the third quarter of 2019, up 78% as compared to the third quarter of 2018. The strong cash flow performance was the result of higher sales and improved profitability resulting from our efficiency initiatives. During the third quarter, the Company repurchased 1.9 million shares, at a total cost of \$100 million and paid a dividend of \$20 million, bringing the total cash returned to shareholders to \$120 million in the third quarter.

Segment Results

Consumables Segment

Consumables sales grew 1.8% to \$416 million, and increased 3.2% on an internal sales growth basis. This performance was driven by growth in sales of Restorative and Endodontics products, partially offset by a modest decline in Laboratory Dental product sales.

Technologies & Equipment Segment

Technologies & Equipment sales grew 5.1% to \$535 million and increased 11% on an internal growth basis. Key drivers of this growth were Digital Dentistry (which includes the CAD/CAM and Orthodontics businesses) and Healthcare, offset in part by weakness in Equipment & Instruments sales, mainly a function of ongoing competitive pressures in our Imaging business. Growth in Digital Dentistry was very strong, driven by the successful launch of our Primescan CAD/CAM digital impression scanning system.

Fiscal Year 2019 Outlook

The Company increased the FY19 guidance range for Adjusted Earnings Per Share to \$2.42 to \$2.48.

	Previous Guidance	Updated Guidance
Revenue	\$3.95B to \$4.05B	\$3.95B to \$4.05B
Internal revenue growth ^[3]	4%-5%	Upper end of 4%-5%
Portfolio shaping/M&A revenue impact	(\$60M)	(\$60M)
Foreign currency FY19 impact	(\$100M)	(\$135M)
Adjusted operating income margin ^[3]	18%-19%	18%-19%
Non-GAAP effective tax rate ^[3]	24.75%	24.75%
Adjusted earnings per share ^[3]	\$2.35-\$2.45	\$2.42-\$2.48
Note: 2019 guidance does not incorporate any additional 2019 share repurchase a	ctivity	

^[3] Dentsply Sirona does not provide GAAP financial measures on a forward-looking basis, because the company believes it is unable to provide a meaningful or accurate calculation or estimation of reconciling items and the information is not available without unreasonable effort. These reconciling items include the impact of prospective acquisitions, acquisitions announced but not yet closed and other non-GAAP items, including restructuring costs and various other factors, many of which are difficult to predict.

Recent Announcements & Additional Highlights

Dentsply Sirona World 2019 was hosted in Las Vegas in October and represented a celebration of dentistry combining professional development courses, opportunities for dental professionals to connect with each other and world class entertainment. Dentsply Sirona World 2019 brought together 7,000 dental professionals to celebrate dentistry's cutting-edge technology. Participants accessed over 100 in-depth, clinical education sessions and workshops with over 100 captivating speakers, representing the

best and brightest minds in dentistry. At Dentsply Sirona World 2019, the Company introduced new U.S. product launches including:

- Schick AE Sensor A dental intraoral x-ray sensor that features an Advanced Exposure technology that generates an excellent imaging quality, even at lower x-ray dosage ranges.
- Orthophos, E, S and SL panoramic imaging lines for the U.S. market.
- The Astra Tech implant system EV developed to provide excellent initial stability for improved outcomes in any type of bone, either for delayed load or immediate load cases.
- Trunatomy Endodontic Files an innovative and minimally invasive endodontic file system.
- 3D Dental Printing of Dentures A joint venture that utilizes the Carbon 3D printer and new Dentsply Sirona materials to create high quality, durable 3D printed dentures.
- Updated CEREC 5.1 Software a performance upgrade for CEREC. The addition of OraCheck allows dentists to visualize three-dimensional changes on virtual optical scans over time on their own computer.

Appointed New Board Member

The Company announced that Janet S. Vergis was appointed to its Board of Directors, increasing the size of its Board from ten to eleven members.

Conference Call/Webcast Information

Dentsply Sirona's management team will host an investor conference call and live webcast on November 7, at 8:30 am ET. A presentation will also be available on www.dentsplysirona.com in the Investors section.

Investors can access the webcast via a link on Dentsply Sirona's web site at www.dentsplysirona.com. For those planning to participate on the call, please dial +1-877-370-7637 for domestic calls, or +1-629-228-0723 for international calls. The Conference ID # is 8769438. A replay of the conference call will be available online on the Dentsply Sirona web site, and a dial-in replay will be available for one week following the call at +1-855-859-2056 (for domestic calls) or +1-404-537-3406 (for international calls), replay passcode # 8769438.

About Dentsply Sirona

Dentsply Sirona is the world's largest manufacturer of professional dental products and technologies, with a 132-year history of innovation and service to the dental industry and patients worldwide. Dentsply Sirona develops, manufactures, and markets a comprehensive solutions offering including dental and oral health products as well as other consumable medical devices under a strong portfolio of world class brands. As The Dental Solutions Company, Dentsply Sirona's products provide innovative, high-quality and effective solutions to advance patient care and deliver better, safer and faster dentistry. The Company's shares of common stock are listed in the United States on Nasdaq under the symbol XRAY. Visit www.dentsplysirona.com for more information about Dentsply Sirona and its products.

Contact Information:

Investors: John Sweeney, CFA, IRC Vice President, Investor Relations +1-717-849-7863 John.Sweeney@dentsplysirona.com

Forward-Looking Statements and Associated Risks

Information the Company has included or incorporated by reference in this Form 8-K, and information which may be contained in other filings with the U. S. Securities and Exchange Commission (the "SEC") as well as press releases or other public statements, contains or may contain forward-looking statements. These forward-looking statements include, among other things, statements about the completion of the year-end financial statement audit and expected financial results referred to herein, and/or statements about the Company's plans, objectives, expectations (financial or otherwise) or intentions, including the Company's 2019 guidance.

The Company's forward-looking statements involve risks and uncertainties. Actual results may differ significantly from those projected or suggested in any forward-looking statements. The Company does not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances occurring after the date hereof or to reflect the occurrence of unanticipated events. Any number of factors could cause the Company's actual results to differ materially from those contemplated by any forward-looking statements, including, but not limited to, the risks associated with the following:

- the preliminary nature of the financial results contained in this release
- the Company's ability to successfully implement its cost reduction and restructuring plans
- the Company's ability to remain profitable in a very competitive marketplace, which depends upon the Company's ability to differentiate its products and services from those of competitors
- the Company's failure to anticipate and appropriately adapt to changes or trends within the rapidly changing dental industry
- the effect of changes in the Company's management and personnel
- changes in applicable laws, rules or regulations, or their interpretation or enforcement, or the enactment of new laws, rules
 or regulations, which apply to the Company's business practices (past, present or future) or require the Company to spend
 significant resources for compliance
- a significant failure or disruption in service within the Company's operations or the operations of key distributors
- results in pending and future litigation, investigations or other proceedings which could subject the Company to significant
 monetary damages or penalties and/or require us to change our business practices, or the costs incurred in connection
 with such proceedings
- the Company's failure to attract and retain talented employees, or to manage succession and retention for its Chief Executive Officer or other key executives
- the Company's failure to successfully integrate the business operations or achieve the anticipated benefits from any acquired businesses
- the Company's failure to execute on, or other issues arising under, certain key client contracts
- the impact of the Company's debt service obligations on the availability of funds for other business purposes, the terms of and required compliance with covenants relating to the Company's indebtedness and its access to the credit markets in general

- general economic conditions
- other risks described from time to time in the Company's filings with the SEC

You should carefully consider these and other relevant factors, including those risk factors in Part I, Item 1A, "Risk Factors" in the Company's most recent Form 10-K and any other information included or incorporated by reference in this Report, and information which may be contained in the Company's other filings with the SEC, when reviewing any forward-looking statement. Investors should understand it is impossible to predict or identify all such factors or risks. As such, you should not consider either foregoing lists, or the risks identified in the Company's SEC filings, to be a complete discussion of all potential risks or uncertainties associated with an investment in the company.

Non-US GAAP Financial Measures

The principal measurements used by the Company in evaluating its business are: (1) constant currency sales growth by segment and geographic region; (2) internal sales growth by segment and geographic region; and (3) adjusted operating income and margins of each reportable segment, which excludes the impacts of purchase accounting, corporate expenses, and certain other items to enhance the comparability of results period to period. These principal measurements are not calculated in accordance with accounting principles generally accepted in the United States; therefore, these items represent non-US GAAP measures. These non-US GAAP measures may differ from other companies and should not be considered in isolation from, or as a substitute for, measures of financial performance prepared in accordance with US GAAP.

The Company defines "constant currency" sales growth as the increase or decrease in net sales from period to period excluding precious metal content and the impact of changes in foreign currency exchange rates. This impact is calculated by comparing current-period revenues to prior-period revenues, with both periods converted at the U.S. dollar to local currency foreign exchange rate for each month of the prior period, for the currencies in which the Company does business. The Company defines "internal" sales growth as constant currency sales growth excluding the impacts of net acquisitions and divestitures and discontinued products.

Management believes that the presentation of net sales, excluding precious metal content, provides useful information to investors because a portion of Dentsply Sirona's net sales is comprised of sales of precious metals generated through sales of the Company's precious metal dental alloy products, which are used by third parties to construct crown and bridge materials. Due to the fluctuations of precious metal prices and because the cost of the precious metal content of the Company's sales is largely passed through to customers and has minimal effect on earnings, Dentsply Sirona reports net sales both with and without precious metal content to show the Company's performance independent of precious metal price volatility and to enhance comparability of performance between periods. The Company uses its cost of precious metal purchased as a proxy for the precious metal content of sales, as the precious metal content of sales is not separately tracked and invoiced to customers. The Company believes that it is reasonable to use the cost of precious metal content purchased in this manner since precious metal dental alloy sale prices are typically adjusted when the prices of underlying precious metals change.

In addition to the results reported in accordance with US GAAP, the Company provides adjusted net income attributable to Dentsply Sirona and adjusted earnings per diluted common share ("adjusted EPS"). The Company discloses adjusted net income attributable to Dentsply Sirona to allow investors to evaluate the performance of the Company's operations exclusive of certain items that impact the comparability of results from period to period and may not be indicative of past or future performance of the normal operations of the Company and certain large non-cash charges related to intangible assets either purchased or acquired through a business combination. The Company believes that this information is helpful in understanding underlying operating trends and cash flow generation.

Adjusted net income and adjusted EPS are important internal measures for the Company. Senior management receives a monthly analysis of operating results that includes adjusted net income and adjusted EPS and the performance of the Company is measured on this basis along with other performance metrics.

The adjusted net income attributable to Dentsply Sirona consists of net income attributable to Dentsply Sirona adjusted to exclude the following:

(1) Business combination related costs and fair value adjustments. These adjustments include costs related to integrating and consummating mergers and recently acquired businesses, as well as costs, gains and losses related to the disposal of businesses or significant product lines.

In addition, this category includes the roll off to the consolidated statements of operations of fair value adjustments related to business combinations, except for amortization expense noted below. These items are irregular in timing and as such may not be indicative of past and future performance of the Company and are therefore excluded to allow investors to better understand underlying operating trends.

(2) Restructuring program related costs and other costs. These adjustments include costs related to the implementation of restructuring initiatives as well as certain other costs. These costs can include, but are not limited to, severance costs, facility closure costs, lease and contract terminations costs, related professional service costs, duplicate facility and labor costs associated with specific restructuring initiatives, as well as, legal settlements and impairments of assets. These items are irregular in timing, amount and impact to the Company's financial performance. As such, these items may not be indicative of past and future performance of the Company and are therefore excluded for the purpose of understanding underlying operating trends.

(3) *Amortization of purchased intangible assets.* This adjustment excludes the periodic amortization expense related to purchased intangible assets. Amortization expense has been excluded from adjusted net income attributed to Dentsply Sirona to allow investors to evaluate and understand operating trends excluding these large non-cash charges.

(4) *Credit risk and fair value adjustments.* These adjustments include both the cost and income impacts of adjustments in certain assets and liabilities including the Company's pension obligations, that are recorded through net income which are due solely to the changes in fair value and credit risk. These items can be variable and driven more by market conditions than the Company's operating performance. As such, these items may not be indicative of past and future performance of the Company and therefore are excluded for comparability purposes.

(5) *Gain on sale of marketable securities.* This adjustment represents the gain on the sale of marketable securities held by the Company. The gain has been excluded from adjusted net income attributed to Dentsply Sirona to allow investors to evaluate and understand operating trends excluding this gain.

(6) *Income tax related adjustments.* These adjustments include both income tax expenses and income tax benefits that are representative of income tax adjustments mostly related to prior periods, as well as the final settlement of income tax audits, and discrete tax items resulting from the implementation of restructuring initiatives and the vesting and exercise of employee share-based compensation. These adjustments are irregular in timing and amount and may significantly impact the Company's operating performance. As such, these items may not be indicative of past and future performance of the Company and therefore are excluded for comparability purposes.

Adjusted earnings per diluted common share is calculated by dividing adjusted net income (loss) attributable to Dentsply Sirona by diluted weighted-average common shares outstanding. Adjusted net income attributable to Dentsply Sirona and adjusted earnings per diluted common share are considered measures not calculated in accordance with US GAAP, and therefore are non-US GAAP measures. These non-US GAAP measures may differ from other companies. Income tax related adjustments may include the impact to adjust the interim effective income tax rate to the expected annual effective tax rate. The non-US GAAP financial information should not be considered in isolation from, or as a substitute for, measures of financial performance prepared in accordance with US GAAP.

DENTSPLY SIRONA INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS

(In millions, except per share amounts and percentages) (unaudited)

		Three Mo Septer				Nine Moi Septe		
		2019		2018		2019		2018
Net sales	\$	962.1	\$	928.4	\$	2,917.7	\$	2,926.6
Net sales, excluding precious metal content		950.6		920.6		2,886.1		2,899.1
Cost of products sold		448.1		452.3		1,363.2		1,383.6
Gross profit		514.0		476.1		1,554.5		1,543.0
Selling, general and administrative expenses		399.3		418.5		1,262.1		1,285.9
Goodwill impairment		—		—		_		1,085.8
Restructuring and other costs		5.2		12.1		68.1		211.2
Operating income (loss)		109.5		45.5		224.3		(1,039.9)
Net interest and other expense (income)		3.0		13.8		16.4		(4.1)
Income (loss) before income taxes		106.5		31.7		207.9		(1,035.8)
Provision (benefit) for income taxes		21.5		4.2		47.3		(23.4)
Net income (loss)		85.0		27.5		160.6		(1,012.4)
Less: Net (loss) income attributable to noncontrolling interest		-		(0.5)		—		0.4
Net income (loss) attributable to Dentsply Sirona	\$	85.0	\$	28.0	\$	160.6	\$	(1,012.8)
Net income (loss) per common share attributable to Dentsply Sirona:								
Basic Diluted	\$ \$	0.38 0.38	\$ \$	0.13 0.13	\$ \$	0.72 0.71	\$ \$	(4.50) (4.50)
								()
Weighted average common shares outstanding:								
Basic		223.1		222.4		223.5		224.9
Diluted		224.9		223.7		225.2		224.9

DENTSPLY SIRONA INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (In millions)

(unaudited)

senter	nher 30 2019	Decem	nber 31, 2018
		Beech	1501 51, 2010
\$		\$	309.6
			701.9
			598.9
	281.7		277.6
	1,811.3		1,888.0
	782.5		870.6
	156.7		_
	2,167.7		2,420.3
			3,431.3
	92.9		76.8
\$	8,366.8	\$	8,687.0
\$	246.3	\$	283.9
	541.0		578.9
	69.9		58.1
	11.7		92.4
	868.9		1,013.3
	1,403.9		1,564.9
	118.5		_
	500.7		552.8
	415.7		423.0
	3,307.7		3,554.0
	5,059.1		5,133.0
\$	8,366.8	\$	8,687.0
	\$ 	698.4 605.1 281.7 1,811.3 782.5 156.7 2,167.7 3,355.7 92.9 \$ 8,366.8 \$ 246.3 541.0 69.9 11.7 868.9 1,403.9 118.5 500.7 415.7 3,307.7 5,059.1	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$

DENTSPLY SIRONA INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In millions) (unaudited)

Abjectments to recorde net income to net cash provided by operating activities: 10.6 10. Concorded net income to net cash provided by operating activities: 12.2 12.1 Anortzation of intengible assets: 2.1 12.2 12.2 Faced Asset Impairment 33.4 12.2 12			s Ended Se	eptember 30,
spectra controlspectra controlspectraspectraDepreciation14.2614.26Annotzation of interget reacts prototed by operating activities:14.2614.26Annotzation of interget reacts prototed by operating activities:14.2614.26Annotzation of interget reacts prototed by operating activities:33.410.26Annotzation of interget reacts:33.410.26Defered income taxes:34.4610.26Solva baid compression: requeres and spectra3.810.26Restructuring and other costs: run cash5.312.72Define level interget inserties:3.810.26Cobrin income functions and property, itera relevances3.810.26Cobrin income functions activities:3.810.26Cobrin income functions activities:3.4010.26Cobrin income functions activities:3.5010.26Cobrin income functions activities:3.5010.26Cobrin income functions activities:3.5010.26Cobrin income functions act		2019		2018
digstment by recording entitioner to net cash provided by operating activities: 10 10 Amortazion of determent function gosts 2.1 10 Amortazion of determent function gosts 2.1 10 Exel Asset impainment 33.4 10 Exel Asset compensation expenses (39.9) (9 Exel Asset compensation expenses 43.8 11 Beartmenting and deter costs - non-cash 15.2 1 Goottall impainment	Cash flows from operating activities:			
Dependation 101.6 101.6 Amortariation of interreg financing costs 2.1 101.6 Field Asset financing be assets (20.9) (20.9) Deferred financing be assets (20.9) (20.9) Sock basid compression coports (20.9) (20.9) Restructing and tabler costs - non ceah 5.3 101.000 Deferred intergible asset inpairment 5.3 101.000 Interfaction divers inspace of property plant and copingent 2.9 3.0 Casts on adge of non-strategic businesses or product fines (10.0) (10.0) Casts on adge of non-strategic businesses or product fines (10.0) (10.0) Casts on adge of non-strategic businesses or product fines (10.0) (10.0) Casts on adge of non-strategic businesses or product fines (10.0) (10.0) Cast on state or process and fibrities, net of acquestions: (10.0) (10.0) Accounts and notes recorceable - curvent assets, net (10.0) (10.0) (10.0) Accounts and notes recorceable - curvent assets, net (10.0) (10.0) (10.0) Accounts and or pacreable notes recorceable -	let income (loss)	\$ 160).6 \$	(1,012.4
Anonzano of intragble assets142.9142.9Anonzano of diverget function costs2.1Find Assult impairment33.4Destructuring and other costs - non-cash15.2Destructuring and other costs - non-cash15.2Destructuring and other costs - non-cash3.3Destructuring and other costs - non-cash3.3Accounts and notes - recovable trade, not3.3Accounts and notes - recovable trade, not3.3Accounts and notes - recovable trade, not3.3.5Destructuring pathele3.3.5Accounts and notes - recovable trade, not3.3.5Destructuring pathele3.3.5Account patheletis3.4.5	djustments to reconcile net income to net cash provided by operating activities:			
Anotinization of defined framesing cosis 2.1 3.1 Deferred income taxes (39.9) (0 Socis based compression expenses (39.9) (0 Restructioning and other costs - non cash 15.2 1 Restructioning and other costs - non cash 5.3 17 Definite-level intergible asset impairment 5.3 17 Definite-level intergible asset impairment 5.3 17 Definite-level intergible asset impairment 5.3 17 Case on disposal of proporty, plant and explantent 2.9 3.1 Case on disposal of proporty, plant and explantent 6.9 1.0 Case on sale of explant sectors 1.0 1.0 1.0 Changes on operating assets and habilities, net of acquations:	Depreciation	10:	6	103.4
Ened Asset Impairment 33.4 Deferred income taxes (39.9) (0) Stock based componsation repense 49.8 (1) Restructuring and other costs - non-cash 13.2 (1) Order in costs in costs 13.3 (1) Deferred income taxes (2,4) (C) Loss on disposat of property, fait and equipment 2.9 (2) Cash on divestiture of non-costh income (2,4) (C) Cash on divestiture of non-costhing interest (8,7) (2) Cash on divestiture of non-costhing interest (2,7) (2) Cash on divestiture of non-costhing interest (3,6) (4) Changes in operating assets and libelities, net o acquisitions: (3,6) (4) Uncontons, ond (3,6) (4) (3,6) Other non-cost in accost in accost on accost in accost on accost in accost on accost in accost in accost on accost in accost on accost in accost	Amortization of intangible assets	142	2.9	149.7
Deferred income taxes(39.9)(9)Bestructuring and other costs - non-cash11.21Goodell inpairment-1.06Restructuring and other costs - non-cash11.21Definite-lowed manpile asset inpairment-1.06Coller non-cash income(2.4)(0)Other non-cash income(2.4)(0)Coller non-cash income(2.4)(0)Coller non-cash income(2.4)(0)Coller non-cash income(2.7)-Cash on asia of ong viscurity(4)Changes in operating assess and liabilities, net of acuisitions:Changes in operating assess and liabilities, net of acuisitions:Propoid cognese and other current assets, net(3.6)(4)Other non-cash inters reservable frade, net(3.6)(2,6)Accurate and inters reservable frade, net(3.6)(2,6)Accurate and tabilities(3.6)(2,6)(2,6)Cole non-current assets, net(3.6)(2,6)(2,6)Accurate provided by operating activities(3.6)(2,6)(2,6)Cole non-current assets, net(3.6)(3,7)(2,7)Accurate provided by operating activities(3,6)(3,7)(2,7)Cole non-current assets, net(3,6)(3,7)(3,7)Accurate provided by operating activities(3,6)(3,7)(3,7)Cole non-current assets, net(3,7)(3,7)(3,7)Cole non-current assets, net(3,7)(3,7)(3,7) <td>Amortization of deferred financing costs</td> <td>:</td> <td>2.1</td> <td>2.0</td>	Amortization of deferred financing costs	:	2.1	2.0
Stock based compensation expension 48.8 1 Genotavili inpairment	Fixed Asset Impairment	33	3.4	-
Restructuring and other costs - non-cash15.21Definition-lived intangable asset inpairment3.31.7Definitio-lived intangable asset inpairment3.81.0Definition-lived intangable asset inpairment3.81.0Definition-lived intangable asset inpairment2.93.3Definition-lived intangable asset inpairment6.71.0Loss on disposition of protecting interest6.71.0Charges in operating assets and liabilies, red f acquisitions:	Deferred income taxes	(39	1.9)	(97.9
GoodWillingamment1.08Inderhite-lived intangible asset impairment5.31.7Definite-lived intangible asset impairment3.81.7Coller non-cash income(2.24)(.1Case on abgood of properby, plant and equipment2.92.3Case on abgood of properby, plant and equipment2.93.8Case on abgood of properby, plant and equipment(8.7)-Case on abgood of properby, plant and equipment(8.7)-Can on able of equity security-(4.4)(8.8)Canops in operating assets and liabilities, net of acquisitions:-(4.4)(8.8)Prepaid expenses and other current assets, net(3.6)(4.4)(9.8)Other noncurrent assets, net(3.6)(1.4)(1.4)(1.4)Accounds payable(3.6)(1.4)(1.4)(1.4)Accounds payable(3.6)(1.4)(1.4)(1.4)Accounds payable(3.5)(2.9)(3.3)(3.3)Cother noncurrent liabilities4.6(3.6)(3.3)(1.3)Cother services of short term investments-(0.1)(0.1)(3.3)(1.3)Cother acquisitions of businesces and equip investments, net of cash acquired(3.3)(1.3)(1.3)Cother acquisitions of businesces and equip investments, net of cash acquired(3.3)(1.3)(1.3)Cother acquisitions of businesces and equip investments, net of cash acquired(3.3)(1.3)(1.3)Cother acquisitions of businesces and equip investments, n	Stock based compensation expense	49).8	15.1
indefinite-lived intangible asset impairment5.317Definite-lived intangible asset impairment3.80Uses on disposal of property plant and equipment2.93Loss on adjosto of property plant and equipment8.70Can on sate of non-strategic businesses or product lines14.00Changes in operating assets and liabilities, net of acquisitions:-6.47Accounts and notes receivable trade, net(20.7)2.20Inventionies, net(36.1)(44.4)(41.4)Accounts and notes receivable trade, net(35.5)(11.4)1.1Accounts and notes receivable trade, net(35.5)(11.4)1.1Accounts and notes receivable trade(35.5)(11.4)1.1Accounts and notes receivable trade(31.6)(31.6)(31.6)Internet taxes(36.6)(13.1)(13.1)1.11.1Accounts and notes receivable trade(33.1)(33.6)(31.6)(33.6)(31.6)Interaction of short term investments-(11.6)1.61.6Interaction of short term investments-(11.6)1.61.6Interaction of short term investments-(11.6)1.61.6 <tr<< td=""><td>Restructuring and other costs - non-cash</td><td>1</td><td>5.2</td><td>19.2</td></tr<<>	Restructuring and other costs - non-cash	1	5.2	19.2
Definite-work additional set in the set	Goodwill impairment		_	1,085.8
Other non-cash income (12.4) (12.4) (12.4) (12.4) (12.4) (12.5)	Indefinite-lived intangible asset impairment	!	5.3	179.2
Loss on disposal of property, plant and equipyment 2.9 Gain on disposal of property, plant and equipyment (8.7) Gain on sele of equipy security — (4.7) Gain on sele of equipy security — (4.7) Cannes in operating assets and liabilities, net of acquisitions: (3.6) (4.4) (8.7) Accounts and notes receivable-trade, net (3.6) (4.4) (8.7) (3.6) (4.4) (1.4)	Definite-lived intangible asset impairment	:	3.8	-
Gain on divestitue of noncointrolling interests(8.7)Loss on slate of non strategic businesses or product lines14.0Changes in operating assets and liabilities, net of acquisitions:(20.7)Inventories, net(20.7)Inventories, net(20.7)Constrated notes receivable-trade, net(20.6)Other noncurrent assets, net(20.5)Changes and other current assets, net(20.5)Changes and other current assets, net(20.5)Changes and other current assets, net(20.5)Change and the current assets, net(20.6)Change and the current assets, net(20.6) </td <td>Other non-cash income</td> <td>(12</td> <td>2.4)</td> <td>(2.0</td>	Other non-cash income	(12	2.4)	(2.0
Loss on sale of non-stategic businesses or product lines 14.0 Changes in operating assets and liabilities, net of acquisitions: (20.7) Accounts and notes receivable-trade, net of (3.6) (44.4) (3.6) Prepaid expenses and lobilities, net of acquisitions: (3.6) (45.6) (44.4) (14.4) (10.4) (14.4) (10.4) (14.4) (10.4) Accounts payable (3.5) (15.6) (4.6) (16.7) (2.7) Accounts payable (3.5) (16.7) (2.6) Account liabilities (3.6) (16.7) (2.6) (16.7) (2.6) (16.7) (2.6) (16.7) (2.6) (16.7) (2.6) (16.7) (2.6) (16.7) (2.6) (16.7) (2.6) (16.7) (2.7) (16.7) (2.7) (16.7) (2.7) (16.7) (2.7) (16.7) (2.7) (16.7) (2.7) (16.7) (2.7) (16.7) (2.7) (16.7) (2.7) (16.7) (2.7) (16.7) <	Loss on disposal of property, plant and equipment	:	2.9	2.7
Gain on sale of equity security — (4 Changes in operating assets and liabilities, net of acquisitions: (20,7) 2 Inventionies, net (20,7) 2 Inventionies, net (48,4) (8 Prepaid expenses and other current assets, net (3,6) (4 Other noncurrent assets, net (14,4) (0,1) Accounts and notes receivable (11,4) (14,4) (14,4) Accounts payable (35,5) (1 Accounts and liabilities (35,5) (1 Other noncurrent liabilities (36,6) (33) Other noncurrent liabilities (36,6) (33) Unchased for them investing activities (36,6) (33) appliel appenditures (36,6) (33) (13) unchase of short term investinents	Gain on divestiture of noncontrolling interest	(8	3.7)	_
Changes in operating assets and liabilities, net of acquisitions: (20,7) 2 Accounts and notes receivable-trade, net (20,7) 2 Inventories, net (3,6) (44,4) (8) Prepaid expenses and other current assets, net (3,6) (44,4) (10,4) (10,4) (10,4) (10,4) (10,4) (11,4)	Loss on sale of non-strategic businesses or product lines	14	4.0	_
Accounts and notes receivable-frade, net (20,7) 2 Inventories, net (48.4) (68 Prepaid expenses and other current assets, net (3.6) (4 Other noncurrent assets, net (14.4) (14.4) Accounts payable (3.5) (1 Accounts payable (35.5) (1 Income taxes 11.4 1 Other noncurrent liabilities 4.6 (0 Cher noncurrent liabilities 4.6 (1 Other noncurrent liabilities 4.6 (1 Cher noncurrent liabilities 4.6 (1 Cher noncurrent liabilities 4.6 (1 Cher noncurrent liabilities 333.5 29 Cash flows from investing activities: 333.5 29 Cash paid or accivities 4.6 (1 Cher noncurrent liabilities - (0 Stath sele of ont term investimes - (0 Cher as de sele of ont investime activities: - (0 Stath feered on derivative contracts - (0	Gain on sale of equity security		_	(44.:
Inventiois, net (48.4) (88. Prepaid expenses and other current assets, net (3.6) (44.4) Other noncurrent assets, net (3.6) (14.4) Accrued liabilities (3.6) (14.4) Accrued liabilities (3.6) (11.4) (11.4) Other noncurrent liabilities 4.6 (C) Income taxes 11.4 (11.4) (11.4) Other noncurrent liabilities 4.6 (C) Ide cash provided by operating activities: 333.5 2.9 Cash flows from investing activities: - (0.6) iguidation of short term investments - (0.1) Cash paid for acquisitions of businesses and equity investments, net of cash acquired (3.3) (13.3) Cash received on derivative contracts - (C) (C) Cash received on derivative contracts - (C) (C) Cash flows from financing activities: - (C) (C) Cash paid on derivative contracts - (C) (C) Cash paid on derivative contracts -	Changes in operating assets and liabilities, net of acquisitions:			
Prepaid expenses and other current assets, net (3.6) (4 Other noncurrent assets, net (3.6) (4 Other noncurrent assets, net (3.6) (1 Accounts payable (30.5) (1) Accounts payable (35.5) (1) Other noncurrent liabilities 4.6 (1) Cleast provided by operating activities: 333.5 29 Cash flows from investing activities:	Accounts and notes receivable-trade, net	(20).7)	25.3
Other noncurrent assets, net (14.4) (14.4) Accuruls payable (30.5) 11.4 Accurul fiabilities (35.5) (1 Income taxes 11.4 11 Other noncurrent liabilities 4.6 (2 it cash provided by operating activities: 333.5 29 cash flows from investing activities: 333.5 29 cash flows from investing activities:	Inventories, net	(48	3.4)	(83.3
Accounts payable (30.5) 11 Accound liabilities (35.5) (1) Income taxes (1).4 12 Other noncurrent liabilities 33.5 29 cash flows from investing activities: (86.9) (1)3 cash flows from investments (86.9) (1)3 cash flows from investments 0.1 (3.3) cash paid acquisitions of bior term investments 0.1 (3.3) cash paid or acquisitions of businesses and equity investments, net of cash acquired (3.3) (1.3) trocaeds from sale of equity security	Prepaid expenses and other current assets, net	(3	3.6)	(47.3
Accrued liabilities (35.5) (1 Income taxes 11.4 11.5 11.6 1	Other noncurrent assets, net	(14	1.4)	(10.3
Income taxes 11.4 11.4 11.4 Other noncurrent liabilities 4.6 (C) let cash provided by operating activities 333.5 2.9 cash flows from investing activities: 333.5 2.9 captilities of short term investments (B6.9) (13) curchase of short term investments 0.1	Accounts payable	(30).5)	10.
Other noncurrent liabilities 4.6 (f) Other noncurrent liabilities 333.5 29 isah flows from investing activities: (86.9) (1.3) iquidation of short term investments	Accrued liabilities	(35	5.5)	(7.:
iet cash provided by operating activities 333.5 29 cash flows from investing activities: (86.9) (13) cash paid for acquisitions of businesses and equity investments. 0.1 (3) cash paid for acquisitions of businesses and equity investments. 0.1 (3) cash paid for acquisitions of businesses and equity investments, net of cash acquired (3,3) (13) rocceeds from sale of equity security 5 cash received on derivative contracts 345.5 (3) cash paid on derivative contracts (0) cash received on derivative contracts (0) cash paid on contracts (3.3) (13) cash paid on treasury stock (39.7) (20) cash paid for treasury stock (160.0) (25) cash paid for treasury stock (30.7) (30.7) trocceeds from long-term borrowings (37.0) (21)	Income taxes			13.
Stach flows from investing activities: Sapital expenditures (86.9) (13) Varchase of short term investments 0.1 0.1 iquidation of short term investments 0.1 0.1 Sash paid for acquisitions of businesses and equily investments, net of cash acquired (3.3) (1.3) Scash received for sale of equivy security - 55 Scash received for sale of non-strategic businesses and product lines 11.6 - Scash received on derivative contracts 34.5 - - Scash paid on derivative contracts - (0.1) - - Yapenditures for identifiable intragible assets - (0.1) - - (0.1) Yapenditures for identifiable intragible assets - (0.1) - (0.1) - - (0.1) Yapenditures for identifiable intragible assets - (0.1) - (0.2) - (0.2) - (0.2) - (0.2) - (0.2) - (0.2) - (0.2) - (0.2) - (0.2) - (0.2) - (0.2) - - (0.2)	Other noncurrent liabilities		1.6	(3.
capital expenditures (66.9) (13) functase of short term investments (0) iquidation of short term investments 0.1 (13) iquidation of short term investments 0.1 (13) iquidation of short term investments (3.3) (13) icash paid of acquisitions of businesses and equity investments, net of cash acquired (3.3) (13) icash paid on derivative contracts (0) (2) cash paid on derivative contracts (0) (2) ice cash used in investing activities (39,7) (2) (2) ice cash paid for term investing activities (16,0) (25) (25) cash paid for contingent consideration on prior acquisitions (30,7) (2) (2) cash paid for contingent consideration on prior acquisitions (30,7) (let cash provided by operating activities	33	3.5	297.6
Purchase of short term investments	Cash flows from investing activities:			
iquidation of short term investments0.1Cash paid for acquisitions of businesses and equity investments, net of cash acquired(3.3)(13)broceeds from sale of equity security—5cash received for sale of non-strategic businesses and product lines11.65Cash received on derivative contracts34.53cash paid on derivative contracts—(CCash received for sale of property, plant and equipment, net4.31det cash used in investing activities(37)(20)Cash paid for reasury stock(160.0)(25)Cash dividends paid(58.7)(5)Cash dividends paid(58.7)(5)Cash dividents contracts(30.7)(20)Proceeds from exercise of stock options(30.7)(20)Proceeds from exercise of stock options(370.3)(17)Cash dividends paid(58.7)(5)Creceds from exercise of stock options78.82Cash used in financing activities(370.3)(17)Creceds from long-term borrowings(370.3)(17)Creceds from long-term borrowings(370.3)(17)Creceds from long-term borrowings(38.5)(6)Cash used in financing activities(7.0)(0)Creceds from exercise of stock options(83.5)(6)Cash dividends paid or contingent consideration on prior acquisitions(32)(2)Creceds from long-term borrowings(370.3)(17)Creceds from long-term borrowings(30.6)(3) <td>Capital expenditures</td> <td>(86</td> <td>i.9)</td> <td>(130.6</td>	Capital expenditures	(86	i.9)	(130.6
iquidation of short term investments0.1cash paid for acquisitions of businesses and equity investments, net of cash acquired(3.3)(13)troceeds from sale of equity security-5cash received for sale of non-strategic businesses and product lines11.6-cash received on derivative contracts34.5-(10)cash paid on derivative contracts-(10)(10)cash paid on derivative contracts-(10)(10)cash paid on derivative contracts-(10)(10)cash paid on derivative contracts-(10)(10)cocceds from sale of property, plant and equipment, net4.3-(10)tect cash used in investing activities(39.7)(20)(20)cash paid for tracsury stock(160.0)(25)(25)cash dividends paid(58.7)(53)(53)(53)cash dividends paid(58.7)(53)(10)(25)cash dividends paid(58.7)(53)(10)(25)croceeds from long-term borrowings118.9-(10)(25)croceeds from long-term borrowings(18.9)(10)(25)(10)croceeds from exercise of stock options(78.8)2(20)croceeds from exercise of stock options(78.8)2(20)croceeds in cash and cash equivalents(70)(10)(25)croceeds in cash and cash equivalents(70)(10)(25)cash paid for contingent consideration on prior acquisition	Purchase of short term investments		_	(0.1
Proceeds from sale of equity security—5ash received for sale of non-strategic businesses and product lines11.6cash received on derivative contracts34.5cash paid on derivative contracts—cash paid on derivative contracts—cash paid on derivative contracts—core des from sale of property, plant and equipment, net4.3let cash used in investing activities(39.7)cash paid for treasury stock(160.0)cash paid for treasury stock(160.0)cash paid for treasury stock(30.7)croceeds from long-term borrowings118.9cash paid for contingent consideration on prior acquisitions(30.7)croceeds from exercise of stock options78.8cash used in financing activities(37.0.3)croceeds from exercise of stock options78.8cash paid for continger ternsport(37.0.3)croceeds from exercise of stock options78.8cash used in financing activities(37.0.3)croceeds from exercise of stock options78.8cash used in financing activities(7.0)cifect of exchange rate changes on cash and cash equivalents(7.0)cifect of exchange rate changes on cash and cash equivalents(83.5)cifect of exchange rate changes on cash and cash equivalents(30.9)cifect of exchange rate changes on cash and cash equivalents(30.9)cifect of exchange rate changes on cash and cash equivalents(30.9)cifect of exchange rate changes on cash and cash equivalents(30.9)	iquidation of short term investments	().1	_
Proceeds from sale of equity security—5Cash received for sale of non-strategic businesses and product lines11.6Cash received on derivative contracts34.5Cash paid on derivative contracts—Cash paid on derivative contracts—Cash paid on derivative contracts—Cash paid on derivative contracts—Croceeds from sale of property, plant and equipment, net4.3Vertex stor identifiable intangible assets—Croceeds from financing activities(39.7)Cash paid for treasury stock(160.0)Cash paid for treasury stock(160.0)Cash paid for contingent consideration on prior acquisitions(30.7)Proceeds from long-term borrowings118.9Cash paid for contingent consideration on prior acquisitions(37.3)Proceeds from exercise of stock options78.8Cash used in financing activities(37.3)Croceeds from exercise of stock options78.8Cash used in financing activities(17.0)Croceeds from exercise of stock options(38.5)Cash and cash equivalents(7.0)Croceeds from exercise of stock options(38.5)Croceeds from exercise of stock options(38.5)Cash and cash equivalents(7.0)Croceeds in cash and cash equivalents(7.0)Croceeds from exercise of stock options(38.5)Cash and cash equivalents at beginning of period(30.9)	Cash paid for acquisitions of businesses and equity investments, net of cash acquired	(3	3.3)	(130.5
tash received for sale of non-strategic businesses and product lines11.6tash received on derivative contracts34.5tash paid on derivative contracts—tash paid on derivative contracts—torce des from sale of property, plant and equipment, net4.3tet cash used in investing activities(39.7)tet cash used in investing activities:(67.4)tet payments on short-term borrowings(67.4)tet ash paid for treasury stock(160.0)tash flows from financing activities:(30.7)treasure store sto			_	54.:
Scash received on derivative contracts34.5Cash paid on derivative contracts—(1)Cash paid on derivative contracts—(2)Croceeds from sale of property, plant and equipment, net4.3(3)Let cash used in investing activities(3).7)(20)Cash flows from financing activities(67.4)12Cash paid for treasury stock(160.0)(25)Cash dividends paid(58.7)(5)Cash paid for contingent consideration on prior acquisitions(30.7)Proceeds from long-term borrowings(18.9)(17)Proceeds from long-term borrowings(251.2)(17)Croceeds from long-term borrowings(251.2)(17)Croceeds from long-term borrowings(261.2)(17)Croceeds from long-term borrowings(270.3)(17)Croceeds from exercise of stock options78.822Croceeds from exercise of stock options(36.5)(8)Croceeds in financing activities(7.0)(17)Croceeds from exercise of stock options(36.5)(8)Croceeds from exercise of stock options(36.5)(8)Croc		1:	.6	_
Cash paid on derivative contracts	- · · ·	34	1.5	3.1
Expenditures for identifiable intangible assets—(()Proceeds from sale of property, plant and equipment, net4.3(20)Let cash used in investing activities(39.7)(20)Cash flows from financing activities:(67.4)12Repayments on short-term borrowings(67.4)12Cash paid for treasury stock(160.0)(25)Cash paid for treasury stock(160.0)(25)Cash paid for contingent consideration on prior acquisitions(30.7)Proceeds from long-term borrowings118.9(10)Cash paid for contingent consideration on prior acquisitions(30.7)Proceeds from exercise of stock options78.822Let cash used in financing activities(370.3)(17)Effect of exchange rate changes on cash and cash equivalents(7.0)(4)Let decrease in cash and cash equivalents(83.5)(8)Cash and cash equivalents at beginning of period309.6322	Cash paid on derivative contracts			(2.4
Proceeds from sale of property, plant and equipment, net4.3Let cash used in investing activities(39.7)Cash flows from financing activities:Repayments on short-term borrowings(67.4)Cash paid for treasury stock(160.0)Cash paid for treasury stock(160.0)Cash paid for contingent consideration on prior acquisitions(30.7)Proceeds from long-term borrowings118.9Cash paid for contingent consideration on prior acquisitions(30.7)Proceeds from long-term borrowings118.9Cash used in financing activities(370.3)Cash used in financing activities(370.3)Cash used in financing activities(370.3)Cash used in financing activities(30.7)Cash used in financing activities(370.3)Cash used in financing activities(370.3)Cash used in financing activities(370.3)Cash and cash equivalents(83.5)Cash and cash equivalents at beginning of period309.6Cash and cash equivalents at beginning of period20.9.6				(5.5
Vet cash used in investing activities(39.7)(200Cash flows from financing activities: Repayments on short-term borrowings(67.4)12.Cash paid for treasury stock(160.0)(250Cash dividends paid(58.7)(53.7)Cash paid for contingent consideration on prior acquisitions(30.7)Proceeds from long-term borrowings118.9Repayments on long-term borrowings(251.2)Proceeds from exercise of stock options78.8Stet cash used in financing activities(370.3)Effect of exchange rate changes on cash and cash equivalents(7.0)Cash and cash equivalents at beginning of period309.6Cash and cash equivalents at beginning of period22			4.3	6.3
Repayments on short-term borrowings(67.4)12Cash paid for treasury stock(160.0)(256Cash paid for contingent consideration on prior acquisitions(58.7)(57Cash paid for contingent consideration on prior acquisitions(30.7)(18.9)Proceeds from long-term borrowings(251.2)(17Proceeds from exercise of stock options78.822Proceeds from exercise of stock options(370.3)(17Effect of exchange rate changes on cash and cash equivalents(83.5)(8Cash and cash equivalents at beginning of period309.6322Cash and cash equivalents at beginning of period(10.1)(10.1)				(205.0
Repayments on short-term borrowings(67.4)12Cash paid for treasury stock(160.0)(256Cash paid for contingent consideration on prior acquisitions(58.7)(57Cash paid for contingent consideration on prior acquisitions(30.7)(18.9)Proceeds from long-term borrowings(251.2)(17Proceeds from exercise of stock options78.822Proceeds from exercise of stock options(370.3)(17Effect of exchange rate changes on cash and cash equivalents(83.5)(8Cash and cash equivalents at beginning of period309.6322Cash and cash equivalents at beginning of period(10.1)(10.1)	Cash flows from financing activities:			
Cash paid for treasury stock(160.0)(256Cash paid for contingent consideration on prior acquisitions(58.7)(58Cash paid for contingent consideration on prior acquisitions(30.7)(30.7)Proceeds from long-term borrowings118.9(251.2)Proceeds from exercise of stock options78.822Let cash used in financing activities(370.3)(172Effect of exchange rate changes on cash and cash equivalents(7.0)(162Let decrease in cash and cash equivalents(330.5)(82Cash and cash equivalents at beginning of period309.6322Cash and cash equivalents309.6322Cash and cash equivalents309.6 </td <td>-</td> <td>(67</td> <td>'.4)</td> <td>124.3</td>	-	(67	'.4)	124.3
Cash dividends paid(58.7)(58.7)Cash paid for contingent consideration on prior acquisitions(30.7)Proceeds from long-term borrowings118.9Repayments on long-term borrowings(251.2)Proceeds from exercise of stock options78.8Let cash used in financing activities(370.3)Effect of exchange rate changes on cash and cash equivalents(7.0)Let decrease in cash and cash equivalents(83.5)Cash and cash equivalents at beginning of period309.6Cash and cash equivalents at beginning of period309.6		,	,	(250.2
Cash paid for contingent consideration on prior acquisitions(30.7)Proceeds from long-term borrowings118.9Repayments on long-term borrowings(251.2)Proceeds from exercise of stock options78.8Jet cash used in financing activities(370.3)Effect of exchange rate changes on cash and cash equivalents(7.0)Let decrease in cash and cash equivalents(83.5)Cash and cash equivalents at beginning of period309.6Cash and cash equivalents at beginning of period100.6			-	(59.1
Proceeds from long-term borrowings 118.9 Repayments on long-term borrowings (251.2) Proceeds from exercise of stock options 78.8 Jet cash used in financing activities (370.3) Effect of exchange rate changes on cash and cash equivalents (7.0) Let decrease in cash and cash equivalents (83.5) Cash and cash equivalents at beginning of period 309.6	•		-	_
Repayments on long-term borrowings(251.2)(1Proceeds from exercise of stock options78.82Iet cash used in financing activities(370.3)(17)Effect of exchange rate changes on cash and cash equivalents(7.0)(2Iet decrease in cash and cash equivalents(83.5)(8)Cash and cash equivalents at beginning of period309.6322				0.3
Proceeds from exercise of stock options 78.8 2 Let cash used in financing activities (370.3) (17) Effect of exchange rate changes on cash and cash equivalents (7.0) (4) Let decrease in cash and cash equivalents (83.5) (8) Cash and cash equivalents at beginning of period 309.6 322				(9.3
let cash used in financing activities (370.3) (172 iffect of exchange rate changes on cash and cash equivalents (7.0) (4 let decrease in cash and cash equivalents (83.5) (8 Cash and cash equivalents at beginning of period 309.6 322			-	22.8
let decrease in cash and cash equivalents(83.5)(8Cash and cash equivalents at beginning of period309.632				(171.2
let decrease in cash and cash equivalents(83.5)(8Cash and cash equivalents at beginning of period309.632	ffect of exchange rate changes on cash and cash equivalents	(*	⁷ .0)	(8.
Cash and cash equivalents at beginning of period 309.6 32				(0
	· · ·	,	,	320.6
Cash and cash equivalents at end of period \$ 226.1 \$ 233				233.2

DENTSPLY SIRONA INC. AND SUBSIDIARIES

(In millions, except percentages)

(unaudited)

A reconciliation of reported net sales to non-GAAP net sales, excluding precious metal content, is as follows:

	Thr	ee Months En	ded Se	ptember 30,	
(in millions, except percentages)		2019		2018	Variance %
Net sales	\$	962.1	\$	928.4	3.6 %
Less: precious metal content of sales		11.5		7.8	47.4 %
Net sales, excluding precious metal content		950.6		920.6	3.3 %
Acquisition related adjustments (a)		—		3.2	NM
Non-GAAP, net sales, excluding precious metal content	\$	950.6	\$	923.8	2.9 %
Foreign exchange impact					(2.3 %)
Constant currency growth					5.2 %
Acquisitions					(1.2 %)
Discontinued products					(1.1 %)
Internal sales growth				_	7.5 %

NM - Not meaningful

(a) Represents an adjustment to reflect deferred revenue that was eliminated under business combination accounting standards.

	Thr	ee M	onths End	led S	eptember	30, 2	2019		Q3	2019 0	Growth			Thre	e Mo	nths Ende	d Se	ptember	30, 20	018
(in millions, except percentages)	 U.S.		Europe		ROW		Total	U.S.	Europ	е	ROW	Total	_	U.S.		Europe		ROW		Total
Net sales	\$ 337.0	\$	361.4	\$	263.7	\$	962.1	2.5 %	3	6 %	5.1 %	3.6 %	\$	328.7	\$	348.8	\$	250.9	\$	928.4
Less: precious metal content of sales	1.5		9.1		0.9		11.5							1.3		5.6		0.9		7.8
Net sales, excluding precious metal content	 335.5		352.3		262.8		950.6	2.5 %	2	7 %	5.1 %	3.3 %		327.4		343.2		250.0		920.6
Acquisition related adjustments(a)	_		_		_		_							3.2		_		_		3.2
Non-GAAP, net sales, excluding precious metal content	\$ 335.5	\$	352.3	\$	262.8	\$	950.6	1.5 %	2	.7 %	5.1 %	2.9 %	\$	330.6	\$	343.2	\$	250.0	\$	923.8
Foreign exchange impact								— %	(4	.6 %)	(2.3 %)	(2.3 %)								
Constant currency growth								1.5 %	7	3 %	7.4 %	5.2 %								
Acquisitions								(2.7 %)	(0	1 %)	(0.6 %)	(1.2 %)								
Discontinued products								(0.4 %)	(1	.0 %)	(2.0 %)	(1.1 %)								
Internal sales growth								4.6 %	8	.4 %	10.0 %	7.5 %								

(a) Represents an adjustment to reflect deferred revenue that was eliminated under business combination accounting standards.

	Three Mo	nths	Ended Septem	ber 3	30, 2019		Q3 2019 Growth				Three Mo	nths End	ed Septem	ber 30), 201 8
(in millions, except percentages)	chnologies & Equipment		Consumables		Total	Technologies & Equipment	c	Consumables	Total		chnologies & Equipment	Cons	umables		Total
Net sales	\$ 534.5	\$	427.6	\$	962.1	5.1 %		1.8 %	3.6 %	\$	508.5	\$	419.9	\$	928.4
Less: precious metal content of sales	_		11.5		11.5						_		7.8		7.8
Net sales, excluding precious metal content	 534.5		416.1		950.6	5.1 %		1.0 %	3.3 %		508.5		412.1		920.6
Acquisition related adjustments ^(a)	-		_		_						3.2		_		3.2
Non-GAAP, net sales, excluding precious metal content	\$ 534.5	\$	416.1	\$	950.6	4.5 %		1.0 %	2.9 %	\$	511.7	\$	412.1	\$	923.8
Foreign exchange impact						(2.4 %)		(2.2 %)	(2.3 %)	-					
Constant currency growth						6.9 %		3.2 %	5.2 %						
Acquisitions						(2.1 %)		— %	(1.2 %)						
Discontinued products						(2.0 %)		— %	(1.1 %)						
Internal sales growth						11.0 %		3.2 %	7.5 %						

(a) Represents an adjustment to reflect deferred revenue that was eliminated under business combination accounting standards.

DENTSPLY SIRONA INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF INCOME

(In millions)

(unaudited)

	GAAP								NON-GAAP
	Three Months Ended September 30, 2019	Amortization of Purchased Intangible Assets	Restructuring Program Related Costs and Other Costs	Business Combination Related Costs and Fair Value Adjustments	Credit Risk and Fair Value Adjustments	Tax Impact of Non-GAAP Adjustments	Income Tax Related Adjustments	Total Non-GAAP Adjustments	Three Months Ended September 30, 2019
NET SALES	\$ 962.1	_	_	_	_	_	_	\$ _	\$ 962.1
NET SALES-excluding precious metals	950.6	_	_	_	—	_	_	_	950.6
GROSS PROFIT	514.0	28.8	3.6	1.5	—	_	—	33.9	547.9
% OF NET SALES-excluding precious metals	54.1 %								57.6 %
SG&A EXPENSES	399.3	(18.6)	(4.8)	(0.3)	—	—	-	(23.7)	375.6
% OF NET SALES-excluding precious metals	42.0 %								39.5 %
RESTRUCTURING AND OTHER COSTS	5.2	—	(5.2)	—	—	—	—	(5.2)	—
INCOME FROM OPERATIONS	109.5	47.4	13.6	1.8	—	—	—	62.8	172.3
% OF NET SALES-excluding precious metals	11.5 %								18.1 %
NET INTEREST AND OTHER EXPENSE	3.0	—	0.4	_	(1.6)	_	_	(1.2)	1.8
PRE-TAX INCOME	106.5	47.4	13.2	1.8	1.6	—	—	64.0	170.5
INCOME TAXES	21.5	-	-	-	—	16.5	4.2	20.7	42.2
% OF PRE-TAX INCOME	20.2 %								24.8 %
LESS: NET INCOME ATTRIBUTABLE TO NON- CONTROLLING INTERESTS	_							_	_
NET INCOME ATTRIBUTABLE TO DENTSPLY SIRONA	\$ 85.0							\$ 43.3	\$ 128.3
% OF NET SALES-excluding precious metals	8.9 %								13.5 %
EARNINGS PER SHARE - DILUTED	\$ 0.38							\$ 0.19	\$ 0.57

DENTSPLY SIRONA INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF INCOME

(In millions)

(unaudited)

	GAAP								NON-GAAP
	Three Months Ended September 30, 2018	Amortization of Purchased Intangible Assets	Restructuring Program Related Costs and Other Costs	Business Combination Related Costs and Fair Value Adjustments	Credit Risk and Fair Value Adjustments	Tax Impact of Non-GAAP Adjustments	Income Tax Related Adjustments	Total Non-GAAP Adjustments	Three Months Ended September 30, 2018
NET SALES	\$ 928.4	_	_	3.2	_	_	_	\$ 3.2	\$ 931.6
NET SALES-excluding precious metals	920.6	-	-	3.2	_	-	-	3.2	923.8
GROSS PROFIT	476.1	29.7	1.6	4.7	_	—	-	36.0	512.1
% OF NET SALES-excluding precious metals	51.7 %								55.4 %
SG&A EXPENSES	418.5	(19.9)	(4.9)	(1.8)	_	-	-	(26.6)	391.9
% OF NET SALES-excluding precious metals	45.5 %								42.4 %
GOODWILL IMPAIRMENT	—	—	—	—	—	—	—	-	—
RESTRUCTURING AND OTHER COSTS	12.1	_	(12.1)	_	_	_	_	(12.1)	—
INCOME FROM OPERATIONS	45.5	49.6	18.6	6.5	—	—	—	74.7	120.2
% OF NET SALES-excluding precious metals	4.9 %								13.0 %
NET INTEREST AND OTHER EXPENSE	13.8	_	—	(0.2)	(2.2)	—	—	(2.4)	11.4
PRE-TAX INCOME	31.7	49.6	18.6	6.7	2.2	—	_	77.1	108.8
INCOME TAXES	4.2	—	-	—	—	20.8	(0.3)	20.5	24.7
% OF PRE-TAX INCOME	13.2 %								22.7 %
LESS: NET INCOME ATTRIBUTABLE TO NON- CONTROLLING INTERESTS	(0.5)							_	(0.5)
NET INCOME ATTRIBUTABLE TO DENTSPLY SIRONA	\$ 28.0							\$ 56.6	\$ 84.6
% OF NET SALES-excluding precious metals	3.0 %								9.2 %
EARNINGS PER SHARE - DILUTED	\$ 0.13							\$ 0.25	\$ 0.38